We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Top Buys
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Cigna
CI
$75.1B
| $27M | 1.06% |
96,339
-86,292
| -47% | -$22.5M |
|
27
McKesson
MCK
$98.5B
| $26.5M | 1.04% |
61,955
-4,500
| -7% | -$1.73M |
|
28
argenx
ARGX
$53.7B
| $25.5M | 1% |
65,553
-22,757
| -26% | -$8.95M |
|
29
HCA Healthcare
HCA
$85.6B
| $25M | 0.98% |
82,403
-6,300
| -7% | -$1.75M |
|
30
Stryker
SYK
$127B
| $24.8M | 0.97% |
81,128
+9,550
| +13% | +$2.76M |
|
31
IQVIA
IQV
$35.1B
| $24.5M | 0.96% |
109,129
+46,012
| +73% | +$9.24M |
|
32
Zoetis
ZTS
$32.2B
| $23.6M | 0.92% |
136,914
| – | – |
|
33
Charles River Laboratories
CRL
$11B
| $23.4M | 0.91% |
111,183
-6,900
| -6% | -$1.37M |
|
|
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
| $21.6M | 0.85% |
112,331
-112,332
| -50% | -$22.3M |
|
|
35
Sarepta Therapeutics
SRPT
$1.82B
| $20.5M | 0.8% |
179,437
-106,216
| -37% | -$13.7M |
|
|
NVO
36
Novo Nordisk
NVO
$228B
| $19.9M | 0.78% |
245,554
+22,908
| +10% | +$1.87M |
|
37
Molina Healthcare
MOH
$11.7B
| $18.6M | 0.73% |
61,856
| – | – |
|
38
Jazz Pharmaceuticals
JAZZ
$15.2B
| $18.3M | 0.72% |
147,779
| – | – |
|
39
BioMarin Pharmaceuticals
BMRN
$11.6B
| $18.3M | 0.72% |
210,789
-89,300
| -30% | -$8.4M |
|
40
Edwards Lifesciences
EW
$50.6B
| $17.9M | 0.7% |
189,597
+18,451
| +11% | +$1.6M |
|
41
Humana
HUM
$46.4B
| $16.5M | 0.64% |
36,794
| – | – |
|
|
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
| $15.8M | 0.62% |
173,248
+38,124
| +28% | +$3.29M |
|
|
43
Baxter International
BAX
$12.1B
| $14.8M | 0.58% |
324,370
+257,058
| +382% | +$11.2M |
|
44
Exelixis
EXEL
$14B
| $13.9M | 0.54% |
726,639
| – | – |
|
45
Novartis
NVS
$291B
| $13.7M | 0.54% |
136,225
| – | – |
|
|
KRTX
46
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $12.7M | 0.5% |
58,577
+5,125
| +10% | +$1.1M |
|
|
47
Insulet
PODD
$11.4B
| $12.6M | 0.49% |
+43,847
| New | +$13.3M |
|
48
Guardant Health
GH
$20.6B
| $12.4M | 0.48% |
346,084
-126,100
| -27% | -$3.62M |
|
49
Ascendis Pharma A/S
ASND
$17B
| $12.4M | 0.48% |
138,791
+15,000
| +12% | +$1.31M |
|
50
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $12.3M | 0.48% |
147,677
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM